References

1. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease
   https://www.hda.org.uk/
   https://www.fda.gov/search?s=Huntington%27s+disease
2. https://search.nih.gov/search?affiliate=nih&query=Antibody+development
3. Bartl S., Queslati A., Southwell A., Siddu A., Parth M., Maxan D.L., A., Salhat N., Burkert M., Mairhofer A., Friedrich T., Pankevych H., Balazs K., Staffler G., Hayden M., Cicchetti F. and Smrzka OW.; The use of monoclonal antibodies to target extracellular mutant huntingtin: Implications for the treatment of Huntington’s disease. Neurobiol Dis. 2020 May 11:104943. doi: 10.1016/j.nbd.2020.104943
   https://pubmed.ncbi.nlm.nih.gov/32407769/
4. Bartl S., Xie Y., Potluri N., Kesineni R., Hencak K., Cengio L.D, Balazs K., Oueslati A., Parth M., Salhat N., Siddu A., Smrzka O., Cicchetti F., Straffler G., Hayden M.R. and Southwell A.L.; Reducing central and peripheral huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease; 2024, in press
   https://doi.org/10.1016/j.nbd.2023.106376
5. https://search.nih.gov/search?affiliate=nih&query=Alzheimer%27s+disease+antibody+treatent&commit=Search